IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
42.22
-1.81 (-4.11%)
As of 12:40PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close44.03
Open44.25
Bid42.15 x 2200
Ask42.19 x 800
Day's Range42.09 - 44.85
52 Week Range39.07 - 65.51
Volume560,939
Avg. Volume1,277,937
Market Cap5.299B
Beta3.34
PE Ratio (TTM)N/A
EPS (TTM)-0.13
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est58.50
Trade prices are not sourced from all markets
  • Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs
    Investor's Business Daily21 hours ago

    Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs

    PTC Therapeutics spiked Wednesday after an analyst suggested it and Roche could rout Biogen and Ionis Pharmaceuticals in treating spinal muscular atrophy.

  • Don't Get Too Excited About PTC Therapeutics (Yet)
    Motley Foolyesterday

    Don't Get Too Excited About PTC Therapeutics (Yet)

    PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.

  • Biogen and Ionis Crash on PTC Therapeutics’ Promising Data
    Market Realist2 days ago

    Biogen and Ionis Crash on PTC Therapeutics’ Promising Data

    Biogen and Ionis Crash on PTC Therapeutics' Promising DataPTC Therapeutics presented positive data on its SMA drug under trial

  • How Financially Strong Is Ionis Pharmaceuticals Inc (NASDAQ:IONS)?
    Simply Wall St.3 days ago

    How Financially Strong Is Ionis Pharmaceuticals Inc (NASDAQ:IONS)?

    Mid-caps stocks, like Ionis Pharmaceuticals Inc (NASDAQ:IONS) with a market capitalization of US$5.85B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...

  • Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle
    Motley Fool3 days ago

    Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle

    Investors value a new round of data for PTC's spinal muscular atrophy drug.

  • PR Newswire3 days ago

    Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer

    CARLSBAD, Calif., June 18, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) today announced that Damien McDevitt, Ph.D. has joined the company as chief business officer. Just this year, Ionis has seen its first commercial drug for a neurological disease, SPINRAZA, reach blockbuster status.

  • GlobeNewswire8 days ago

    Detailed Research: Economic Perspectives on CarGurus, ArcelorMittal, Capricor Therapeutics, B&G Foods, Ionis Pharmaceuticals, and Photronics — What Drives Growth in Today's Competitive Landscape

    NEW YORK, June 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CarGurus, ...

  • GlobeNewswire8 days ago

    Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference

    Research includes clinical trial data across broad SMA patient populations, expanding scientific understanding of SMA and SPINRAZA® (nusinersen)    Study presented examines neurofilament (pNF-H) as a potential ...

  • GlobeNewswire8 days ago

    Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference

    Research includes clinical trial data across broad SMA patient populations, expanding scientific understanding of SMA and SPINRAZA ® Study presented examines neurofilament as a potential biomarker for ...

  • GlobeNewswire8 days ago

    Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat people with serious and rare diseases, today announced completion of a new study to assess the burden of people living with Familial Chylomicronemia Syndrome (FCS) and its impact on their daily lives. Results from the study known as Re-FOCUS were published on June 11, 2018 in the peer-reviewed journal Expert Review of Cardiovascular Therapy. The web-based global study was conducted among people with FCS treated with volanesorsen, Akcea`s investigational therapy currently under regulatory review in the US, EU and Canada.

  • GlobeNewswire8 days ago

    Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat people with serious and rare diseases, today announced completion of a new study to assess the burden of people living with Familial Chylomicronemia Syndrome (FCS) and its impact on their daily lives. Results from the study known as Re-FOCUS were published on June 11, 2018 in the peer-reviewed journal Expert Review of Cardiovascular Therapy. The web-based global study was conducted among people with FCS treated with volanesorsen, Akcea’s investigational therapy currently under regulatory review in the US, EU and Canada.

  • Barrons.com10 days ago

    Biogen Buys $625 Million in Ionis Stock

    Biogen (BIIB) completed a pact to collaborate with Ionis Pharmaceuticals (IONS), and bought 11.5 million Ionis shares for $625 million, paying $54.34 each. Biogen also invested $375 million as an upfront payment to Ionis to "jointly discover and develop novel antisense drugs for a broad range of neurological diseases," as stated in a press release. In total, Biogen laid out $1 billion in cash.

  • PR Newswire16 days ago

    Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases

    CARLSBAD, Calif., June 5, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it closed its expanded strategic collaboration with Biogen (BIIB) to discover and develop novel antisense drugs for a broad range of neurological diseases following receipt of clearance under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. Biogen paid Ionis $1 billion in cash, which included $625 million for the purchase of 11,501,153 shares of Ionis common stock at a price of $54.34 per share and a $375 million upfront payment. On April 20, 2018, Ionis and Biogen announced they would expand their strategic collaboration to develop novel antisense drugs for a broad range of neurological diseases through a new ten-year collaboration.

  • 3 Top Biotech Stocks to Buy in June
    Motley Fool17 days ago

    3 Top Biotech Stocks to Buy in June

    The cure for your portfolio's ills might be found in these three mid-cap biotech stocks.

  • Better Buy: Biogen Inc. vs. Celgene
    Motley Fool18 days ago

    Better Buy: Biogen Inc. vs. Celgene

    Which of these beaten-down biotech stocks wins in a head-to-head match-up?

  • GlobeNewswire20 days ago

    Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of TEGSEDI(TM) (inotersen) for the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). Click here to read the EMA`s press release. The positive opinion will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union, as well as to European Economic Area members Iceland, Liechtenstein and Norway. "Today`s positive CHMP opinion is an important step toward making TEGSEDI available to people with this systemic, progressive and fatal hereditary disease that relentlessly deprives them of their independence and dignity," said Paula Soteropoulos, chief executive officer at Akcea Therapeutics.

  • GlobeNewswire20 days ago

    Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of TEGSEDI™ (inotersen) for the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). Click here to read the EMA’s press release. The positive opinion will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union, as well as to European Economic Area members Iceland, Liechtenstein and Norway. “Today’s positive CHMP opinion is an important step toward making TEGSEDI available to people with this systemic, progressive and fatal hereditary disease that relentlessly deprives them of their independence and dignity,” said Paula Soteropoulos, chief executive officer at Akcea Therapeutics.

  • The Upside Potential in Editas Medicine Stock
    Market Realist23 days ago

    The Upside Potential in Editas Medicine Stock

    Editas has key collaboration agreements with Juno Therapeutics and Allergan Pharmaceuticals. Of the nine analysts covering Editas Medicine in May, five have given the stock “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “strong sell” rating. The mean rating for the stock is 2.67, and its target price is $45.2, implying an upside potential of 23.4% over its closing price of $36.63 on May 24.

  • How Clovis Oncology’s Cash Flow and Valuation Compare
    Market Realist24 days ago

    How Clovis Oncology’s Cash Flow and Valuation Compare

    In the first quarter, Clovis Oncology’s (CLVS) operating expenses rose YoY (year-over-year) to $100.6 million from $80.4 million, due to a larger net loss and inventories rising. Clovis’s investments fell YoY to $9.8 million from $86.6 million due to the company buying $133 million in available-for-sale securities and selling $50 million in securities in 2017. In the first quarter of this year, Clovis sold $10 million in available-for-sale securities and purchased $217,000 in property and equipment. Clovis generated $226.9 million from financing activities in the first quarter of 2017.

  • What’s Clovis Oncology’s Return Potential?
    Market Realist24 days ago

    What’s Clovis Oncology’s Return Potential?

    Clovis Oncology (CLVS) is a biopharmaceutical company with a focus on acquiring, developing, and commercializing anti-cancer agents. Clovis’s Rubraca (rucaparib), launched in the United States in December 2016, is approved for treating adult patients with deleterious BRCA1-mutation epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received two or more chemotherapies. Of the nine analysts covering Clovis Oncology, seven have recommended “buy” or a higher rating, while two have recommended “hold.” Clovis’s target price of $79.57 implies a 67.4% upside based on the stock’s May 24 closing price of $47.52.

  • What Analysts Think about Ionis
    Market Realist27 days ago

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.

  • How Ionis’s Spinraza Did in Q1
    Market Realist27 days ago

    How Ionis’s Spinraza Did in Q1

    Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is an FDA-approved drug designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease in pediatric patients and adults. Biogen (BIIB), which has held the worldwide development and commercialization rights for Spinraza since January 2012, forwards royalties to Ionis.

  • Analyzing Ionis’s Q1 Revenue Streams
    Market Realist27 days ago

    Analyzing Ionis’s Q1 Revenue Streams

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% YoY (year-over-year) to $144.4 million from $145.3 million. Analysts expect its revenue to grow 30.2% YoY to $135.7 million in the second quarter. The graph below compares Ionis’s revenue since Q1 2017.

  • Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?
    Market Realist27 days ago

    Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?

    How Is Alnylam Pharmaceuticals Positioned in 2018? Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21. Overall, Alnylam Pharmaceuticals has fallen 24%.

  • What Drove Ionis’s Revenue in Q1
    Market Realist28 days ago

    What Drove Ionis’s Revenue in Q1

    In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.